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Summary
Perfluorocarbon nanoparticles functionalized for thom-
bin inhibition with Bivalirudin or PPACK were tested as
an inhibitor of thrombin in vitro and in acute thrombo-
sis models. The particles significantly inhibited occlusive
arterial thrombi. The particles also manifested binding
providing magnetic resonance contrast highlighting
thrombi.
Background
Acute thrombosis is currently addressed with a cocktail
of anticoagulants, antiplatelet agents, and thrombolytics.
Optimization of antithrombotics for clinical use remains
a significant research challenge. Thrombin inhibitors
represent a promising class of anticoagulant. Imaging
contrast agents specific to thrombi would represent a
boon to clinical intervention, enabling monitoring of
thrombosis. In recent work, a thrombin-inhibiting per-
fluorocarbon nanoparticle (PFC NP), functionalized by
the direct thrombin inhibitor, PPACK (Phe(D)-Pro-Arg-
Chloromethylketone), was presented as a prototype for
novel class of targeted antithrombotic. Here, an NP func-
tionalized with Bivalirudin (BVR), was compared to BVR
and the PPACK NP. Both particles were examined as
agents for inhibition and imaging of acute thrombosis.
Methods
PPACK or BVR were covalently attached to PFC NPs.
Optical assay verified that PPACK and BVR selectivity
and activity against thrombin was not diminished on the
NPs. In vivo activity was assessed for PPACK NPs,
PPACK, BVR, BVR NPs, heparin, non-functionalized
NPs, or saline in C57BL6 mice subjected to laser injury
of the carotid artery. Time to thrombotic occlusion of
the injured artery was assessed via Doppler flow mea-
surement. Selected arteries were excised to assess NP
retention via 19F MR at 12T. The laser injury arterial
thrombosis model was applied in cholesterol-fed rabbits
to demonstrate 3T MRI of thrombosis following admin-
istration of PPACK NPs. 19F MRI of the arterial seg-
ment at 12T enabled mapping of the thrombus.
Results
PPACK NPs exceeded PPACK’s activity against throm-
bin. BVR activity on NPs was insignificantly diminished
versus free BVR. Previously, PPACK NPs outperformed
both heparin (p=.001) and PPACK (p=.0006) in delaying
occlusion of the carotid artery. PPACK or non-functio-
nalized NPs failed to delay occlusion of the carotid
artery. BVR NPs significantly delayed occlusion (p=.02)
whereas an equivalent dose of free BVR (120 mg/kg) did
not (figure 1a). 19F MR captured specific PFC NP reten-
tion in occluded arteries (figure 1b), with 19F MRI
demonstrating colocalization of particles with the arter-
ial thrombus and quantitative 19F spectroscopy demon-
strating specificity of BVR or PPACK NP binding.
Ultrasound imaging showed development of thrombi in
rabbits (figure 2a). MRA detected the formed thrombus
(figure 2b). 19F MRI mapped the thrombus via retention
of PPACK NPs.
Conclusions
Anticoagulant PFC NPs were designed as new antith-
rombotics with intrinsic magnetic resonance contrast,
concentrated therapeutic impact conferred by a
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Page 2 of 3thrombin-specific particle surface, and well-defined
pharmacokinetics controlled by the particle itself. As
potent agents that can enhance the therapeutic perfor-
mance of different thrombin inhibitors, these NPs are
promising agents. Further clinical potential is conferred
on the thrombin-inhibiting PFC NP by its ability to
guide further intervention by specifically localizing mag-
netic resonance contrast to sites of thrombosis.
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